Morphea (localized scleroderma) is a skin disorder characterized by inflammation leading to progressive fibrosis and sclerosis of the dermis and subcutaneous tissue. The fascia, muscle, and underlying bone may also be involved. Its underlying etiology is not fully known and its pathogenesis is probably multifactorial. We report a case of a 5-year-old female child with a history of solitary, indurated purple-gray plaque on the right thigh, which gradually increased in size to become a 9x10 cm ill-defined circular, indurated plaque with central area of hypopigmentation and surrounding lilac-colored rim of five months duration. There are various therapeutic options for the treatment of morphea but selection of treatment is done empirically. Colchicine is an easily available and relatively safe drug in the management of plaque type morphea in pediatric patients. The patient was started on topical clobetasol propionate 0.05% ointment twice a day for 4 weeks. Oral prednisone was simultaneously given at 0.5 mg/kg/day for four weeks and slowly tapered over eight weeks. On the 5th week, she was started on colchicine 500 mcg/tab once a day for five weeks. The lesion gradually resolved in a span of 11 weeks. Early diagnosis and treatment this condition is important to prevent irreversible residual symptoms such as atrophy, dyspigmentation and contractures. Colchicine can be a promising alternative to other systemic therapeutic options such as steroids and methotrexate in the treatment of morphea. 

Human ; Female ; Child Preschool ; Albinism, Oculocutaneous ; Atrophy ; Child ; Clobetasol ; Colchicine ; Contracture ; Dermis ; Early Diagnosis ; Fascia ; Inflammation ; Methotrexate ; Prednisone ; Scleroderma, Localized ; Sclerosis ; Skin Diseases ; Subcutaneous Tissue ; Thigh